Research programme: bradykinin B1/2 antagonists - Biofrontera AG
Latest Information Update: 04 Nov 2017
At a glance
- Originator Biofrontera AG
- Class
- Mechanism of Action Bradykinin B1 receptor antagonists; Bradykinin B2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Pain
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in Germany
- 29 Sep 2009 The programme is still in active development
- 15 Mar 2007 Development of this programme is ongoing